Skip to main content

Advertisement

Table 1 Clinicopathological characteristics and mutation status

From: Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis

sample tumor location family history mutation sex age at onset (yrs) multiple
paragangliomas
1 PGL04 CBT PGL2 - f 28 yes
2 PGL01 CBT PGL2 - f 28 yes
3 PGL02 CBT PGL2 - m 37 yes
4 PGL19 CBT PGL2 - f 32 yes
5 PGL05 CBT SDHD D92Y m 43 yes
6 PGL06 CBT SDHD D92Y m 47 yes
7 PGL13 CBT SDHD D92Y f 29 yes
8 PGL14 CBT SDHD D92Y f 45 no
9 PGL16 CBT SDHD D92Y f 47 yes
10 PGL17 CBT SDHD D92Y f 74 no
11 PGL10 CBT SPOR - f 44 no
13 PGL12 CBT SPOR - f 49 no
14 PGL15 CBT SPOR - f 38 no
15 PGL23 CBT SPOR - f 70 no
16 PGL20 CBT SPOR - m 27 no
  1. CBT = carotid body tumor; PGL2 = positive family history for PGL2-linked paragangliomas; SDHD = positive family history for SDHD-linked paragangliomas; SPOR = sporadic sample, negative family history of paraganglioma or phaeochromocytoma and no mutation in the SDHB, SDHC or SDHD gene; D92Y = Asp92Tyr, a Dutch founder mutation in the SDHD gene; m = male patient, f = female patient.